{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:18:14Z","timestamp":1780399094266,"version":"3.54.1"},"reference-count":14,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Among the approved therapies for metastatic hormone\u2010sensitive prostate cancer (mHSPC), abiraterone and docetaxel are administered concomitantly with corticosteroids. This study evaluated the association between corticosteroid use and risk of adverse events among patients with mHSPC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted an observational cohort study among patients \u2265\u200965 years of age who were enrolled in Medicare parts A, B, or D, and initiated treatment for mHSPC. The primary exposure was corticosteroids between June 1, 2017\u2013December 31, 2023. Primary outcomes were nine composite adverse event outcomes. Exploratory outcomes were all\u2010cause death, all\u2010cause hospitalization, and adverse event\u2010related hospitalization. Conventional Cox models were used to model corticosteroid exposure as a binary time\u2010varying covariate, and weighted cumulative exposure models were used to account for varying doses, durations, and timing of corticosteroid exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 24,857 patients, 12,839 (52%) received at least one dose of corticosteroids during the follow\u2010up period. Compared with patients who were not exposed to at least one \u2265\u20095\u2009mg prednisone\u2010equivalent dose of corticosteroids, patients exposed to corticosteroids during follow\u2010up were at significantly higher risk of all adverse event types, except ophthalmic events, and had a 34% higher risk of all\u2010cause death (adjusted hazard ratio: 1.34; 95% confidence interval: 1.27\u20131.42). Risks increased with prolonged corticosteroid exposure and with higher daily doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings suggest that patients exposed to corticosteroids are at increased risk of adverse events, hospitalization, and death. As not all mHSPC treatments require concomitant use of corticosteroids, these findings may help to inform treatment decision\u2010making.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70143","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:31:18Z","timestamp":1770719478000},"page":"763-770","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone\u2010Sensitive Prostate Cancer"],"prefix":"10.1002","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3518-0411","authenticated-orcid":false,"given":"Umang","family":"Swami","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute University of Utah Salt Lake City Utah USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujun","family":"Shao","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamuno","family":"Alfred","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maelys","family":"Touya","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Cao","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinal","family":"Kamdar","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmina","family":"Ivanova","sequence":"additional","affiliation":[{"name":"Pfizer Inc. New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Celli","sequence":"additional","affiliation":[{"name":"ADVI Health Washington DC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Nimke","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development Inc. Northbrook Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003452"},{"key":"e_1_2_11_3_1","unstructured":"National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer. Version 1.2025 published December 4 2024."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70379-0"},{"key":"e_1_2_11_5_1","unstructured":"ZYTIGA (Prescribing Information). Horsham PA: Janssen Biotech Inc.2011."},{"key":"e_1_2_11_6_1","unstructured":"DOCETAXEL (Prescribing Information). Baxter Healthcare Corporation. 2021 accessed September 24 2025 https:\/\/www.baxterpi.com\/pi-pdf\/Docetaxel_PI.pdf."},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0167"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2016.02.010"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds216"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011"},{"key":"e_1_2_11_12_1","unstructured":"PREDNISONE (Prescribing Information). Roxane Laboratories Inc. 2012 accessed May 5 2025 https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Roxane\/Prednisone\/Prednisone%20Tablets%20Oral%20Solution%20and%20Intensol.pdf."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00867-6"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3701"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0430-z"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.70143","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T10:43:42Z","timestamp":1780397022000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,10]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/pros.70143"],"URL":"https:\/\/doi.org\/10.1002\/pros.70143","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,10]]},"assertion":[{"value":"2025-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}